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In this study we analyzed by immunohistochemis-
try the expression of TGF-1 protein and TGF-
receptors I and II in 4 low-grade dysplastic nodules,
2 high-grade dysplastic nodules, 6 early, 22 small,
and 62 advanced hepatocellular carcinomas. The
expression of TGF-1 protein by hepatocytes was
decreased in advanced hepatocellular carcinoma
compared with small or early hepatocellular carci-
noma(P < .05). Frequent and intense staining of
TGF-1 protein was noted in the sinusoidal endo-
thelium of advanced hepatocellular carcinomas de-
spite of its decreased staining in hepatocellular car-
cinoma cells. Reduced expression of TGF-
receptors I and II compared with surrounding non-
tumorous tissue were noted from the early hepato-
cellular carcinoma stage suggesting that down-
regulation of TGF- receptors is correlated with
progression from premalignant to malignant phe-
notype. Reduced expression of both TGF-1 and
TGF- receptor II in neoplastic hepatocytes were
also significantly correlated with increased tumor
size and increased proliferative activity(P < .05).
These findings suggest that during hepatocarcino-
genesis, the inhibitory effects of TGF-1 protein on
hepatocellular carcinoma cells is outweighed by its
effects on stromal elements, which, overall, contrib-
utes indirectly to a tumor growth stimulatory envi-
ronment. Also, the growth-inhibitory effects of
TGF-1 may have been further negated by reduced
TGF- receptors on hepatocellular carcinoma cells.
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TGF- receptor I, TGF- receptor II.
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TGF-1 belongs to a family of polypeptides that
play a central role in the regulation of cell growth
and differentiation within both normal and trans-
formed cells (1). In general, TGF-1 inhibits the
proliferation of normal epithelial cells including
hepatocytes (2– 4). However, the effects of TGF-1
in tumor growth are more complex and controver-
sial in that although they may directly inhibit pro-
liferation of epithelial cancer cells, TGF-1 may
indirectly promote tumor growth by their angio-
genic and immunosuppressive properties and ef-
fects in extracellular matrix (5, 6). TGF-1 is known
to generate these responses by interacting with cell
surface receptors that are ubiquitously expressed:
type I (55 kD), type II (80 kD), and type III (280 kD)
receptors (7). Both TGF- receptor I (TGF- RI) and
TGF- receptor II (TGF- RII) possess intrinsic
serine-threonine kinase activity and signal through
a heteromeric receptor complex (8, 9). TGF- RI
requires TGF- RII to bind ligand whereas TGF-
RII requires the presence of TGF- RI to signal (10).
TGF-1 RIII lacks consensus motif and does not
directly participate in TGF-1 signal transduction
(11). Currently, the loss of functional TGF- RI
and/or RII expression is thought to play a critical
role in the escape of tumor cells from TGF- medi-
ated cell cycle control and thus contribute to car-
cinogenesis (12, 13).
Likewise, previous studies have implicated the
overexpression of TGF-1 and reduced expression of
TGF- receptors in the development of hepatocellular
carcinoma (14–16). However, many of theses studies
were carried out either in vitro or in animal models.
The few in vivo studies that demonstrated TGF-1
expression in human hepatocellular carcinoma tissue
have been limited by the small number of cases pre-
cluding statistical significance (17–19). Moreover, no
study has as yet evaluated the expression of TGF-1
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and TGF- receptors in the premalignant stages of
human hepatocellular carcinoma. In an attempt to
clarify the roles of TGF-1 and its receptors in multi-
stage human hepatocarcinogenesis, we analyzed by
immunohistochemistry the expression of TGF-1 and
TGF- receptors I and II in a series of lesions includ-
ing low-grade dysplastic nodules, high-grade dysplas-
tic nodules, early hepatocellular carcinoma, small
hepatocellular carcinoma and advanced hepatocellu-
lar carcinoma. We then investigated whether there
was a correlationship between the expression of
TGF-1 and its receptors, and the many prognostic
factors including tumor size, histologic grade, pres-
ence of vascular invasion, serum alpha-fetoprotein
and proliferative index.
MATERIALS AND METHODS
A total of 96 cases of hepatocellular carcinoma
and dysplastic nodules in surgically resected spec-
imens were selected from the files of the depart-
ment of surgical pathology of Yonsei University,
College of Medicine.
All of the available hematoxylin and eosin-stained
slides were reviewed for all cases. Dysplastic nodules
were classified as low-grade or high-grade according
to the criteria and nomenclature of International
Working Party of the Terminology of Nodular Lesions
of the Liver (20). Lesions with microfoci of hepatocel-
lular carcinoma arising from dysplastic nodules were
defined as early hepatocellular carcinoma (21–23). Le-
sions composed entirely of hepatocellular carcinoma
without evidence of dysplastic nodules and measur-
ing less than or equal to 3 cm were defined as small
hepatocellular carcinoma (23), whereas those larger
than 3 cm were defined as advanced hepatocellular
carcinoma. The histologic grade of hepatocellular car-
cinoma was based on the Edmondson-Steiner
classification.
Immunohistochemistry
Paraffin-embedded blocks containing sufficient
amount of tumor as well as adjacent nontumorous
tissue and showing minimal necrosis were chosen
from each of the 96 cases. Immunohistochemical
stains were performed with these paraffin blocks
using a streptavidin-biotin complex immunoperox-
idase technique. Primary antibodies used were di-
rected against TGF-1, TGF- RI and TGF- RII
(Santa Cruz Biotechnology, Santa Cruz, CA) and
Ki-67 (Novocastra, Newcastle upon Tyne, United
Kingdom), all at a dilution of 1:100. The polyclonal
antibodies detecting TGF-1 was raised against the
amino acids 328 –352 at the carboxy terminus of the
precursor form of TGF-1 and non-cross-reactive
with TGF-2 or TGF-3; TGF- RI corresponding to
the amino acids 158 to 179 of the precursor form of
TGF- RI, subtype of ALK5, and non-cross-reactive
to TGF- RII; and TGF- RII corresponding to
amino acids 246 to 266 of the precursor form of
TGF- RII and non-cross-reactive with TGF-
RIALK5 (Santa Cruz Biotechnology). The specificity
of these antibodies were demonstrated previously
(24, 25). Briefly, 4-micrometer sections of forma-
lin-fixed, paraffin-embedded blocks were depar-
affinized and hydrated in a series of xylene,
graded alcohols, and water and finally washed in
phosphate-buffered saline (PBS). The sections were
immersed in a thermoresistant container filled with
citrate buffer solution (pH 6.0) and placed in a
pressure cooker and microwaved for 20 minutes.
The sections were cooled at room temperature and
rinsed with PBS. They were then incubated in 3%
hydrogen peroxide for 30 minutes to block endog-
enous peroxidase activity and with normal bovine
serum for another 30 minutes to reduce nonspecific
antibody binding. The sections were then incu-
bated overnight at 4°C with primary antibodies.
After another PBS wash, the slides were further
incubated with biotinylated rabbit anti-mouse an-
tibody for 20 minutes at room temperature. The
slides were washed again then reacted with avidin-
biotin-peroxidase (DAKO, Carpenteria, CA) for 20
minutes followed by incubation with 3-amino-9-
ethylcarbazole chromogen. The sections were fi-
nally counterstained with Mayer’s hematoxylin. To
ensure antibody specificity, control slides were ei-
ther incubated in the absence of primary antibody
or with an unspecific IgG antibody. In both cases no
immunostaining was detected.
Immunoreactivity and distribution pattern of
TGF-1, TGF- RI, and TGF- RII were examined in
both the tumorous and adjacent nontumorous tis-
sue. Immunoreactivity for TGF-1, TGF- RI, and
TGF- RII in hepatocytes were separately scored
according to modification of a previously reported
method (26, 27). This entails a three step categori-
zation. The percentage of the positive cells were
graded on a scale of 0 to 4 (0: negative; 1:
0 –25%; 2: 26 –50%; 3: 51–75%; 4: 76 –100%).
Areas that showed positivity were further quantified
from 0 to 3 by the relative staining intensity (0:
negative; 1: weak; 2: moderate; 3: intense
staining). The final score of 0 to 12 was obtained by
multiplying the intensity and quantification mea-
surements. The proliferative index (Ki-67 labeling
index) was calculated by counting the number of
Ki-67 positive hepatocytes over a total of 1000
hepatocytes under 400 magnification.
Statistical Analysis
The results were expressed as mean  standard
deviation. For statistical analysis, the chi-squared
test and one way ANOVA was used.
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RESULTS
Clinicopathologic Features
A total of 96 cases of hepatocellular carcinoma
and dysplastic nodules were included in this study:
4 low-grade dysplastic nodules (4.2%), 2 high-grade
dysplastic nodules (2.1%), 6 early hepatocellular
carcinoma (6.3%), and 84 hepatocellular carcinoma
(87.5%). Of the 84 cases of hepatocellular carci-
noma, 22 (22.9%) were small hepatocellular carci-
noma and 62 (64.6%) were advanced hepatocellular
carcinoma. The histologic grade of hepatocellular
carcinoma was grade I in 14 cases (15.6%), grade II
in 46 cases (51.1%), and grade III in 30 cases
(33.3%). There were no grade IV hepatocellular car-
cinomas. The histologic grade of early hepatocellu-
lar carcinoma were all grade I.
In 95 of these cases, serologic viral markers were
available revealing 70 (73.2%) HBsAg positive cases
and 6 (6.3%) anti-HCV cases. Nineteen (20.0%)
cases were negative for both HBsAg and anti-HCV.
Cirrhosis was present in the adjacent nontumorous
tissue in 43 cases (44.8%).
Expression Pattern of TGF-1, TGF- RI, and
TGF- RII in Nontumorous Tissue
TGF-1, TGF- RI, and TGF- RII were variably
expressed in many different types of cells in the
nontumorous tissue by immunohistochemical
stain.
In the nontumorous tissue, hepatocytes at the
periphery of cirrhotic nodules and near the border
of the tumor showed frequent and intense cytoplas-
mic staining to TGF-1, whereas periportal hepato-
cytes showed only occasional weak staining (Fig.
1A). Also, the epithelium of metaplastic bile
ductules, especially those situated at the border of
the tumor and present in active cirrhotic nodules
showed intense cytoplasmic staining to TGF-1.
Interestingly, the endothelial cells lining the sinu-
soids of nontumorous tissue were generally nega-
tive to TGF-1 in contrast to those lining the sinu-
soids of advanced hepatocellular carcinoma, which
often displayed strong positivity (Fig. 2). The cyto-
plasm of macrophages were intensely stained with
TGF-1 but the fibroblasts and the fibrous stroma
were negative.
TGF- RI demonstrated diffuse, cytoplasmic
staining in the nonneoplastic hepatocytes. The bile
ductules, bile ducts, vascular smooth muscle wall
and macrophages were also positive to TGF- RI
but the extent and intensity of staining were gen-
erally lower as compared with that of TGF- RII.
The fibroblasts were occasionally positive to TGF-
RI.
TGF- RII showed diffuse and moderately in-
tense staining in the nonneoplastic hepatocytes.
FIGURE 1. Immunohistochemical stain for TGF-1 and TGF- RII in nontumorous liver. TGF-1 expression in regenerating hepatocytes adjacent
to tumor (A) and TGF- RII expression in the hepatocytes at the periphery of cirrhotic nodules (B) and bile ductules (C) (LSAB method, A: 100, B:
10, C: 200).
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Similar to TGF-1, TGF- RII was most intensely
stained in the hepatocytes situated along the pe-
riphery of the cirrhotic nodule and near the border
of the tumor (Fig. 1B). The epithelium of metaplas-
tic bile ductules were similarly intensely stained
with TGF- RII (Fig. 1C). Fibroblasts were occasion-
ally weakly positive to TGF- RII but the fibrous
stroma was always negative.
Positive Rates of TGF-1, TGF- RI, and TGF-
RII Expression in Tumor
The expression rates of TGF-1, TGF- RI, and
TGF- RII in the tumors are summarized in Table 1.
Only those cases showing immunoreactivity in the
hepatocytes comprising the tumor were considered
to be positive. All three antibodies showed a cyto-
plasmic staining pattern in the preneoplastic (Fig.
3) and neoplastic hepatocytes (Fig. 4). Of a total of
96 cases, TGF-1 and TGF- RI expression were
observed in 53 (55.2%) and 77 (80.2%) cases, re-
spectively. TGF- RII was expressed in all the le-
sions (100%). All cases of dysplastic nodules, both
low-grade and high-grade as well as early hepato-
cellular carcinoma universally expressed TGF-1,
TGF- RI, and TGF- RII. However, small and ad-
vanced hepatocellular carcinoma showed de-
creased TGF-1 and TGF- RI positive rates: 63.6%
and 72.7% in small hepatocellular carcinoma, and
43.5% and 79.0% in advanced hepatocellular carci-
noma, respectively.
Staining Scores of TGF-1, TGF- RI, and TGF-
RII in Tumor
The expression levels of TGF-1, TGF- RI, and
TGF- RII in the various stages of hepatocarcino-
genesis were compared by measuring their average
staining scores. The average staining scores for
TGF-1 in the advanced hepatocellular carcinoma
(1.5  2.16) were significantly lower as compared
with that of small hepatocellular carcinoma (3.4 
3.79) (P  .05). TGF-1 was most abundantly ex-
pressed in the low-grade dysplastic nodules (9.5 
3.00). In high-grade dysplastic nodules, the level of
TGF-1 expression (5.0  4.24) was similar to that
of early hepatocellular carcinoma (5.3  2.07).
There was no significant difference in the mean
staining scores for TGF- RI in the various stages of
FIGURE 2. Immunohistochemical stain for TGF-1 in sinusoidal endothelium of cirrhotic nodule and hepatocellular carcinoma. A, Cirrhotic
nodules shows diffuse positive reaction to TGF-1 in the cytoplasm of hepatocytes but negative reaction in the sinusoidal endothelium. B,
Hepatocellular carcinoma shows reverse pattern of TGF-1 staining; negative reaction in the tumor cells and strong positive reaction in the
sinusoidal endothelium (LSAB method, A: 200, B: 40).
TABLE 1. Immunohistochemical Positive Rates of TGF-
1, TGF- receptor I, and TGF- Receptor II in Various
Proliferative Lesions of Liver
Pathologic
Diagnosis
TGF-1 (%)
TGF- RI
(%)
TGF- RII (%)
Low-grade DN 4/4 (100) 4/4 (100) 4/4 (100)
High-grade DN 2/2 (100) 2/2 (100) 2/2 (100)
Early HCC 6/6 (100) 6/6 (100) 6/6 (100)
Small HCC 14/22 (63.6) 16/22 (72.7) 22/22 (100)
Advanced HCC 27/62 (43.5) 49/62 (79.0) 62/62 (100)
Total 53/96 (55.2) 77/96 (80.2) 96/96 (100)
DN, dysplastic nodule; HCC, hepatocellular carcinoma; TGF- RI,
TGF receptor I; TGF- RII, TGF- receptor II.
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hepatocarcinogenesis (Table 2). However, the mean
staining scores of TGF- RI in early hepatocellular
carcinoma (2.8  1.83), small hepatocellular carci-
noma (2.9 3.37) and advanced hepatocellular car-
cinoma (4.1  3.26) revealed to be consistently and
significantly lower as compared with that of corre-
FIGURE 3. Immunohistochemical stain for TGF-1 (A), TGF- RI (B), and TGF- RII (C) in low-grade dysplastic nodule. TGF-1 and its receptors
are expressed in the cytoplasm of hepatocytes (LSAB method, A: 10, B: 40, C: 40).
FIGURE 4. Immunohistochemical stain for TGF-1, TGF- RI, and TGF- RII in hepatocellular carcinoma. A, TGF-1 is focally expressed among
hepatocellular carcinoma cells. B, Note diffuse positive staining of TGF- RI in adjacent normal hepatocytes as compared with negative staining in
hepatocellular carcinoma. C, Reduced expression of TGF- RII in hepatocellular carcinoma (LSAB method, A: 100, B: 40, C: 200).
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sponding nontumorous tissue (6.7  1.63, 9.0 
3.34, 8.4  3.47), respectively (P  .05) (Table 2).
The mean staining scores for TGF- RII showed a
tendency to decrease with tumor progression (Ta-
ble 2), measuring highest in the low-grade dysplas-
tic nodule (9.0  2.0) and lowest in the advanced
hepatocellular carcinoma (6.2  2.59). The mean
staining scores for TGF- RII in advanced hepato-
cellular carcinoma (6.2  2.59) was significantly
lower than that of small hepatocellular carcinoma
(8.1  2.84). As in the case of TGF- RI, the mean
staining scores for TGF- RII in early, small and
advanced hepatocellular carcinoma were signifi-
cantly lower than that of corresponding nontumor-
ous tissue (Table 2). But there was no difference in
the mean staining scores for TGF- RII in the low-
and high-grade dysplastic nodules when compared
with their corresponding nontumorous tissue (Ta-
ble 2).
Correlation of TGF-1, TGF-1 RI, and TGF-1 RII
Expression with Tumor Size, Vascular Invasion,
Serum Alpha-fetoprotein, and Histologic Grade
The expression levels of TGF-1, TGF- RI, and
TGF- RII in tumor correlated with variable clinico-
pathologic factors are summarized in Table 3. TGF-1
expression was inversely correlated with tumor size
and histologic grade (P  .05). Furthermore, de-
creased TGF-1 expression was associated with the
presence of vascular invasion and increased serum
alpha-fetoprotein levels. However, these findings did
not achieve statistical significance.
TGF- RI expression was inversely correlated
with serum alpha-fetoprotein(P  .05). However,
there was no significant correlation between TGF-
RI expression and tumor size, histologic grade and
vascular invasion.
Significant reduction in TGF- RII expression was
found with increased tumor size (P  .05). TGF-
RII also tend to decrease with increase in serum
alpha-fetoprotein levels and advancing histologic
aggressiveness.
Correlation of TGF-1, TGF- RI, and TGF- RII
Expression with Proliferative Index
The proliferative index (Ki-67 score) in various
stages of hepatocarcinogenesis are shown in Fig. 5.
The levels of TGF-1 and TGF- RII expression in
tumor was inversely correlated with the Ki-67 score
(P .05) (Fig. 6, Fig. 7). But there was no significant
correlation between TGF- RI expression and the
Ki-67 score.
DISCUSSION
TGF-1 is an extensively studied cytokine with
diverse biologic activities including regulation of
cell growth and differentiation, control of extracel-
lular matrix formation, angiogenesis and immuno-
modulation (28, 29). Recent studies reveal that
TGF-1 is also involved in the development and
progression of cancer and contrary to its well-
known inhibitory effects on normal epithelial cells,
elevated levels of TGF-1 mRNA have been re-
TABLE 2. Staining Scores of TGF- Receptor I and TGF- Receptor II in Various Proliferative Lesions of Liver as
Compared with Adjacent Nontumorous Liver
Pathologic
Diagnosis
Number
of Cases
TGF- RI TGF- RII
Proliferative
Lesion
Nontumorous
Liver
Proliferative
Lesion
Nontumorous
Liver
Low-grade DN 4 6.0  0 6.5  1.0 9.0  2.0 9.0  2.0
High-grade DN 2 5.0  6.66 5.5  4.95 8.0  0 8.0  0
Early HCC 6 2.8  1.83* 6.7  1.63 7.3  1.63* 9.6  2.66
Small HCC 22 2.9  3.37* 9.0  3.34 8.1  2.84* 10.6  1.92
Advanced HCC 62 4.1  3.26* 8.4  3.47 6.2  2.59* 9.7  2.20
DN, dysplastic nodule; HCC, hepatocellular carcinoma.
Value: mean  standard deviation.
* P  .05, significantly different from that of nontumorous liver.
TGF- RI, TGF- receptor I; TGF- RII, TGF- receptor II.
TABLE 3. Relationship between TGF-1, TGF- Receptor
I, and TGF- Receptor II Expression and Variable
Clinicopathologic Features
Clinicopathologic
Features
TGF- 1 TGF- RI TGF- RII
Tumor size (cm) P  .05 NS P  .05
3 4.1  4.00 3.5  3.25 8.1  2.51
3–5 2.4  2.34 4.2  3.25 7.1  2.81
5 1.3  2.23 3.9  3.28 5.8  2.42
Vascular invasion NS NS NS
Present 1.9  3.16 3.7  3.21 6.9  2.63
Absent 3.0  3.56 4.3  3.26 6.6  2.90
Serum -FP (ng/mL) NS P  .05 NS
20 3.4  3.83 4.8  3.24 7.5  3.21
20–2000 2.2  2.63 3.6  3.22 6.8  2.23
2000 1.9  3.16 2.4  2.87 5.7  2.09
Histologic gradea P  .05 NS NS
I 4.2  3.72 4.6  3.78 8.0  2.60
II 1.8  2.22 3.6  3.16 6.6  2.65
III 1.8  2.97 3.6  3.10 6.3  2.77
Value: mean  standard deviation.
a Edmondson-Steiner grade.
TGF- RI, TGF- Receptor I; TGF- RII, TGF- Receptor II; -FP,
alpha-fetoprotein; NS, not significant.
P  .05, significant.
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ported in many cancers such as liver, lung, breast,
kidney and prostate (14, 15). Furthermore, TGF-1
expression has been associated with increased cell
proliferation in gastric and thyroid cancers (27, 30)
and with disease progression in breast and prostate
cancer (31, 32).
Studies in human gastric, breast and prostate
cancers have claimed the cancer cells as the source
of increased TGF-1 and the overexpression of
TGF-1 protein in these cancer cells have been
confirmed by immunohistochemical stains (27, 31,
32). However, the source and site of TGF-1 expres-
sion in liver is still controversial. It is well estab-
lished that TGF-1 is expressed in nonparenchymal
cells among which Kupffer cells, sinusoidal cells
and transforming rat and human hepatic stellate
cells have been identified as the source of elevated
TGF-1 mRNA and TGF-1 protein in diseased hu-
man and rat liver (33, 34). Until recently, the vast
majority of studies do not point to hepatocytes as
cellular sources of TGF-1 under normal, inflam-
matory and fibrotic conditions. However, more re-
cent studies have not only identified TGF-1 mRNA
and protein in the hepatocytes of long-term-
phenobarbital-treated rats but also displayed that
injured rat hepatocytes are capable of releasing la-
tent TGF-1 during liver regeneration suggesting
hepatocytes as a major source of TGF-1 (35, 36).
Regarding human liver tissue, some authors have
reported hepatocellular carcinoma cells and their
perineoplastic stroma to be immunopositive to
TGF-1 (17, 37), whereas Sue et al. have reported an
absence of TGF-1 immunostaining in hepatocel-
lular carcinoma cells (18).
In the present study using immunohistochemical
staining, TGF-1 expression was detected in the
tumor cells in 53 of the 96 (55.2%) cases of hepato-
cellular carcinoma and dysplastic nodules. The ad-
jacent nonneoplastic hepatocytes showed positivity
to TGF-1 as well and was typically most intensely
stained in the regenerating hepatocytes located
near the border of the tumor and along the periph-
ery of cirrhotic nodules. Similar intense staining
was also observed in the epithelium of metaplastic
bile ductules. Interestingly, the accentuated
TGF-1 staining in these areas colocalized with that
of TGF- RII. TGF-1 was never stained in the
stroma. These immunohistochemical results are
contradictory to two previous reports. In the first
one, Abou-Shady et al. reported intense TGF-1
immunostaining in the hepatocellular carcinoma
cells and the perineoplastic stroma whereas no or
mild immunostaining was present in normal liver
(37). Similarly, the second report by Bedossa et al.
stated that only the neoplastic hepatocytes were
immunoreactive to TGF-1, whereas normal and
cirrhotic hepatocytes were entirely negative (17).
Moreover, in their study, TGF-1 was more fre-
quently stained in the stromal tissue of both the
cirrhotic nodules and hepatocellular carcinoma
rather than the parenchymal cells. The reason for
this discrepancy in immunoreactivity we speculate
is due to the difference in TGF-1 antibody used.
The TGF-1 antibody used in Bedossa’s study
seems to react predominantly with the extracellular
form of TGF-1, whereas the antibody we and per-
haps Sue et al. have used is similar to the LC anti-
TGF-1 antisera (38), which reacts predominantly
with the intracellular forms of TGF-1. The prefer-
FIGURE 5. Ki-67 score in various proliferative lesions of liver. LD,
low-grade dysplastic nodule; HD, high-grade dysplastic nodule; EH,
early hepatocellular carcinoma; SH, small hepatocellular carcinoma;
AH, advanced hepatocellular carcinoma.
FIGURE 6. Negative correlation between TGF-1 expression with Ki-
67 score in various proliferative lesions of liver.
FIGURE 7. Negative correlation between TGF- RII expression and
Ki-67 score in various proliferative lesions of liver.
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ential expression of TGF-1 and TGF- RII in the
regenerating hepatocytes located along the tumor
border, periphery of cirrhotic nodules, and meta-
plastic bile ductules in the non-neoplastic tissue is
in accordance with previous studies that indicated
TGF-1 protein expressed by the regenerating
hepatocytes is involved in preventing uncontrolled
hepatocyte proliferation (3, 4). In another report,
TGF-1 RNA transcripts have been localized by in
situ hybridization to some hepatocytes in the pe-
riphery of regenerating nodules in cirrhotic human
liver suggesting that hepatocytes may well be capa-
ble of expressing the TGF-1 gene even under non-
neoplastic circumstances and that TGF-1 may in-
fluence parenchymal cell growth in distinct areas of
lobule by negative autocrine regulatory loops (39).
Although there is general agreement about the
overexpression of TGF-1 mRNA in hepatocellular
carcinoma, relatively few studies have examined
TGF-1 protein expression in human hepatocellu-
lar carcinomas. Ours is the first to our knowledge to
attempt to compare and characterize TGF-1 ex-
pression in a large series of hepatocellular carcino-
mas including the premalignant stages. By compar-
ing the immunohistochemical scores of TGF-1 in
various stages of hepatocellular carcinoma, we
found that the expression of TGF-1 protein by
tumor cells was significantly decreased in advanced
hepatocellular carcinoma as compared with small
or early hepatocellular carcinoma. Also, TGF-1 ex-
pression in the cancer cells was inversely correlated
with tumor size, proliferative index and histologic
grade. Furthermore, there was a tendency for re-
duced TGF-1 expression in hepatocellular carci-
nomas showing vascular invasion and increased
serum alpha-fetoprotein. Overall, reduced TGF-1
protein expression in the neoplastic hepatocytes
was associated with increased aggressiveness of tu-
mor. A comparable study by Yamaguchi et al. dem-
onstrated that TGF-1 expression in tumor was in-
versely correlated with PCNA labeling index and
tumor size (40). Furuta et al. also indicated that
immunohistochemically TGF-1 was normally ex-
pressed by cancer cells of well differentiated hepa-
tocellular carcinoma, but the expression was weak
or negative in poorly differentiated type (41). Yuen
et al. demonstrated that patients with hepatocellu-
lar carcinoma and patients with cirrhosis of vari-
able causes all had significantly higher serum levels
of total TGF-1 compared with those of controls
(42). However, a lower serum total TGF-1 level was
related to an increased tumor size, which is similar
to the findings of Yamaguchi et al. Yuen et al. sug-
gested that this may be another adaptive mecha-
nism by which the hepatocellular carcinoma mini-
mizes the TGF-1-induced apoptotic effect on the
tumor cells when TGF-1 level exceeds the tumor
tolerable levels (42).
Alternatively, we suggest that the reasons for the
discrepancy between endogenously increased
TGF-1 levels in hepatocellular carcinoma tissue
and decreased expression of TGF-1 protein by
neoplastic hepatocytes in advanced hepatocellular
carcinoma observed in our study may be due to the
discordance between the main sites of TGF-1 syn-
thesis; the neoplastic hepatocytes, and the main
sites of action; perineoplastic stroma. Thus, al-
though there is no doubt about increased produc-
tion of TGF-1 by the hepatocellular carcinoma
cells, the actual effects of increased TGF-1 protein
may be predominantly realized in surrounding
stromal elements by a paracrine mechanism. This
is in keeping with published data that tumor cells
lose the ability to interact with the TGF-1 protein
in an autocrine fashion, and instead indirectly stim-
ulate their growth by the paracrine action of
TGF-1 on supporting stromal elements, which in-
clude suppression of immune response and en-
hancement of both angiogenesis and function of
connective tissue. In support of this theory, we
found in our study that despite of decreased
TGF-1 protein expression by the neoplastic hepa-
tocytes, the endothelial cells lining the sinusoids of
advanced hepatocellular carcinoma were often in-
tensely stained. Interestingly, neither the dysplastic
nodules nor the cirrhotic nodules showed this pat-
tern of TGF-1 staining in the sinusoidal endothe-
lial cells. Factor et al. also underscored the para-
crine effects of TGF-1 during tumor progression
by demonstrating that although the expression of
TGF-1 transgene was found to be reduced or ab-
sent in tumorous relative to nontumorous hepatic
tissue, endogenous TGF-1 mRNA levels were
markedly elevated in most of the tumors appearing
in TGF-1 and c-myc/TGF-1 transgenic mice (43).
However, further serial studies also utilizing an-
tibodies that react with extracellular forms of
TGF-1 or better still, discriminate active and latent
TGF-1 may provide further insights to the rela-
tionship between the expression of TGF-1 and
tumor progression in the present series of patients.
On the other hand, it also has been suggested
that for most cancers, expression of TGF-1 ligand
does not correlate with malignancy, whereas loss of
growth inhibitory response to TGF-1 at the cellu-
lar level is probably a more important step in ma-
lignant progression, and TGF-1 receptors and pro-
teins involved in signaling by TGF-1 appears to act
as tumor suppressors (44).
In our study, using antibodies that recognize the
cytoplasmic domain of the receptors (45– 47),
TGF- RI expression was observed in 80.2% (77 of
96) of cases of hepatocellular carcinoma and dys-
plastic nodules, whereas TGF- RII expression was
observed in all cases (100%). However, semiquan-
titative analysis of the immunohistochemical reac-
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tions showed that the mean staining scores of
TGF- RI and RII in early, small and advanced
hepatocellular carcinoma but not dysplastic nod-
ules were significantly lower than that of surround-
ing nontumorous tissue, suggesting that the re-
duced expression of TGF- receptors is correlated
with development of hepatocellular carcinoma. A
previous study has similarly shown that the degree
of TGF- RII immunolocalization in hepatocellular
carcinoma liver tissue was significantly decreased
compared with those in chronic hepatitis or liver
cirrhosis (45). Moreover, they demonstrated by
western blot analysis that 50% (3 of 6) of the pa-
tients showed an obvious decrease of the TGF- RII
protein in hepatocellular carcinoma tissue com-
pared with that in non-hepatocellular carcinoma
tissue. In the hepatocellular carcinoma tissues in
which TGF- RII expression was not decreased,
they presumed other factors that induce hepatocar-
cinogenesis may be involved (48, 49). Sue et al.,
showed a significant decrease of M6-P/IGF-IIr
(mannose-6-phosphate/insulin-like growth factor
receptor), TGF- RI, and TGF- RII at both the
mRNA and protein levels in hepatocellular carcino-
mas compared with surrounding liver. They sug-
gested that the decreased level of TGF-1 protein in
the malignant epithelial cells of hepatocellular car-
cinoma may result from the decreased expression
of both the M6-P/IGF-IIr and TGF- receptors (18).
Taken together, these data indicate that at least
some cases of hepatocellular carcinoma has re-
duced expression of TGF- receptors for TGF-.
This may provide a selective growth advantage to
hepatocellular carcinoma by escaping the growth-
inhibitory signals of the endogenously increased
TGF-1 and may be linked with critical steps in
hepatocarcinogenesis.
Our study showed that the immunoreactivity of
TGF- RII in advanced hepatocellular carcinoma
was significantly decreased compared with small or
early hepatocellular carcinoma. In addition, tu-
moral TGF- RII immunoreactivity correlated in-
versely with both the tumor size and the tumor
proliferative index, suggesting that down-
regulation of TGF- RII could lead to enhanced
tumor cell proliferation and therefore support tu-
mor progression.
By analogy with colon carcinoma, mutations in one
of the two microsatellites within the TGF- RII coding
region may be responsible for the reduced TGF-
receptor immunoreactivity in hepatocellular carci-
noma (50). In support of this theory, Furuta et al.
demonstrated increasing frequency of inactivating
mutations of the TGF- RII with more aggressive hep-
atocellular carcinomas (41). However, not all reports
support this conclusion (51, 52) and in those cases
without TGF- RII gene mutation, altered regulation
of transcription may negatively influence the stability
or function of the protein. On the other hand, a re-
duction in the detection of TGF- RII by immunohis-
tochemistry could also result if the receptor existed in
a form other than its known functional state, influ-
enced by post-transitional modifications or substrate
bound conformational changes that diminish anti-
body activity.
In conclusion, using immunohistochemistry, we
showed that the TGF-1 protein may be expressed
in a wider variety of hepatocytes than previously
reported, including regenerating hepatocytes, dys-
plastic hepatocytes and hepatocellular carcinoma
cells. Furthermore, the reduced expression of
TGF- RII in the hepatocellular carcinoma cells was
correlated with accelerated tumor growth and in-
creasing malignancy, and the expression of TGF-1
protein by hepatocellular carcinoma cells was
noted to decrease in the course of high-grade pro-
gression. Additional functional and molecular stud-
ies are needed to investigate the etiology of a pos-
sible receptor defect. Whether variation in the
intensity of immunohistochemical staining of the
TGF- RII or TGF-1 provides independent prog-
nostic clinical information will be the subject of
future analysis.
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Book Review
Fletcher DM, Unni KK, Mertens F: Pathology &
Genetics of Tumours of Soft Tissue and
Bone, World Health Organization Classifi-
cation of Tumours, 427 pp, Lyon, Interna-
tional Agency for Research on Cancer
(IARC), 2002 ($75.00).
If you are a member of USCAP or IAP, you could
buy this book for $ 50.00 (fifty dollars, to spell it
out, in case you thought I made a mistake!). This
is a few bucks more than an American patholo-
gist is reimbursed for signing out a case of se-
borrheic keratosis or basal cell carcinoma. If this
is not good enough to entice you to visit the IARC
stand during this year’s annual meeting and take
your own copy home, please keep reading.
This is the fourth volume in the ‘blue books‘
series published by the IARC according to a sim-
ple formula: find three leaders in the field; have
them assemble a team of international experts;
ask the experts to write what they know about
the specific topics of their expertise; convene a
meeting of all parties involved (or at least as
many of those who could make it!) to discuss the
details for a few days, iron out the most glaring
disparities and disagreements, and come up with
the best illustrations possible; and then use the
IARC Press to produce an attractive book at an
affordable price.
As this book shows, the formula worked
again, and I am confident that it will work for the
future books in the series as well. The coverage is
encyclopedic, the text concise but most informa-
tive, the color illustrations of high quality. The
data used to compile the book are current and
reflect the state of affairs in the field of soft tissue
and bone tumors anno Domini 2002. I have no
significant criticism, but to prove that I have
really spent time reading it, I should mention
that some photographs ‘could have been better.‘
I hope that the editors of future additions to the
series will reinforce the zero tolerance policy for
substandard photographs implicit in the first
three volumes!
This book, to quote from the publicity blurb,
was ‘prepared by 147 authors from 28 countries,
contains 966 colour photographs, numerous
x-rays, computer (CT), magnetic resonance (MR)
images, charts, and more than 2,300 references.‘
Dollar for dollar, it is the best bargain on the
market, and a must-buy for your library. While
you are ordering one for yourself, include a few
copies for your best residents. Books of this kind
are excellent publicity for our specialty; if you
need an inexpensive, but nevertheless impres-
sive, gift for your clinical friends, this is a nice
way of showing them what pathology can do for
them. And do not forget to show the ‘blue book‘
to your students to impress upon them how ex-
citing pathology can be, as both a science and a
clinical specialty.
Ivan Damjanov
University of Kansas School of Medicine
Kansas City, Kansas
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